mTOR inhibitors in cancer therapy

被引：259
|
作者：
Zaytseva, Yekaterina Y. [1 ]
Valentino, Joseph D. [1 ,2 ]
Gulhati, Pat [3 ]
Evers, B. Mark [1 ,2 ]
机构：
[1] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA
[2] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA
[3] Univ Texas Med Branch, MD PhD Program, Galveston, TX USA
来源：
CANCER LETTERS | 2012年 / 319卷 / 01期
关键词：
mTOR; Cancer; Cancer therapy; Drug resistance; DUAL PI3K/MTOR INHIBITOR; MAMMALIAN TARGET; CELL MOTILITY; COMPLEX; GROWTH; ACTIVATION; PROLIFERATION; PATHWAY; PHOSPHORYLATION; RICTOR;
D O I：
10.1016/j.canlet.2012.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：1 / 7
页数：7
相关论文
共 50 条
  • [1] mTOR Pathway and mTOR Inhibitors as Agents for Cancer Therapy
    Baldo, Paolo
    Cecco, Sara
    Giacomin, Elisa
    Lazzarini, Renzo
    Rose, Barbara
    Marastoni, Stefano
    CURRENT CANCER DRUG TARGETS, 2008, 8 (08) : 647 - 665
  • [2] mTOR Signaling Pathway and mTOR Inhibitors in Cancer Therapy
    Gomez-Pinillos, Alejandro
    Ferrari, Anna C.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2012, 26 (03) : 483 - +
  • [3] Antihormonal therapy in breast cancer and mTOR inhibitors
    Heudel, Pierre-Etienne
    Tredan, Olivier
    Ray-Coquard, Isabelle
    Treilleux, Isabelle
    Guastalla, Jean-Paul
    Bachelot, Thomas
    BULLETIN DU CANCER, 2011, 98 (12) : 1431 - 1437
  • [4] mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
    Tian, Tian
    Li, Xiaoyi
    Zhang, Jinhua
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (03)
  • [5] Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
    C A Sparks
    D A Guertin
    Oncogene, 2010, 29 : 3733 - 3744
  • [6] Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
    Sparks, C. A.
    Guertin, D. A.
    ONCOGENE, 2010, 29 (26) : 3733 - 3744
  • [7] Metabolic complications with the use of mTOR inhibitors for cancer therapy
    Sivendran, Shanthi
    Agarwal, Neeraj
    Gartrell, Benjamin
    Ying, Jian
    Boucher, Kenneth M.
    Choueiri, Toni K.
    Sonpavde, Guru
    Oh, William K.
    Galsky, Matthew D.
    CANCER TREATMENT REVIEWS, 2014, 40 (01) : 190 - 196
  • [8] mTOR inhibitors in kidney cancer: Template for personalized therapy
    Thomas, George H.
    JOURNAL OF IMMUNOTHERAPY, 2006, 29 (06) : 677 - 677
  • [9] Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
    RuiRong Yuan
    Andrea Kay
    William J Berg
    David Lebwohl
    Journal of Hematology & Oncology, 2
  • [10] mTOR pathway inhibitors in cancer therapy: moving past rapamycin
    Wacheck, Volker
    PHARMACOGENOMICS, 2010, 11 (09) : 1189 - 1191
12345